Teva outlines its accelerated growth strategy focused on innovation, aiming for $5 billion in biopharma revenue by 2030, ...

Teva Pharmaceuticals agreed to pay more than $200 million in fines and divest a key generic drug treating cholesterol to settle price-fixing charges from the US Department of Justice, the agency ...

The Federal Trade Commission has opened an investigation into Teva Pharmaceuticals, citing the company’s refusal to take down about two dozen patents for its asthma and COPD inhalers ...

Aug. 21 (UPI) --Teva Pharmaceuticals has agreed to pay a $225 million fine, in a settlement with the Justice Department over criminal price-fixing charges. According to the deferred prosecution ...

After years of financial problems, downsizing, and dismissals, Israel’s multinational Teva Pharmaceutical Industries Ltd. has been named No. 19 among the top 20 best-earning pharmaceutical ...